Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2584

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2584
---
) programs. However, although multiple preclinical studies are currently
underway, to date, our approach has not been tested in clinical trials for the treatment of NSCLC, GBM or other cancers.

Our
approach to drug discovery and development in the area of fibrosis, with initial focus on targeting chitinase 1, or Chit1, is unproven
and may not result in marketable products. Our approach is designed to discover and develop targeted treatments for idiopathic pulmonary
fibrosis, or IPF, Hermansky-Pudlak Syndrome, or HPS, and possibly other fibrotic diseases, by targeting Chit1 which we have found to
be a master regulator of the TGF-ß1 mediated fibrosis response through various mechanisms. These findings are the basis for our
OCF-203 program. However, although multiple preclinical studies are currently underway, to date, our approach has not been tested in
clinical trials for the treatment of IPF, HPS, or other fibrotic conditions.

Our
approach to therapeutics discovery and development in the area of malaria, with initial focus on targeting P. falciparum glutamic-acid-rich
protein, or PfGARP, and P. falciparum schizont egress antigen, or PfSEA-1, is unproven and may not result in marketable products. Our
approach is designed to discover and develop therapeutics for the treatment of malaria infections and short-term malaria prophylaxis,
and to develop vaccines for immunization against malaria, by targeting PfGARP and PfSEA-1, as applicable. Our findings regarding PfGARP
and PfSEA-1 form the basis for our ODA-611, ODA-579 and OCF-203 programs. However, although multiple preclinical studies are currently
underway, to date, our approach has not been tested in clinical trials for the treatment of malaria infections, to provide malaria prophylaxis
or to provide immunization against malaria.

77

Our
approach to the discovery and development of product candidates based on our Whole Proteome Differential Screening target discovery platform
represents a novel approach to product candidate development, which creates significant challenges for us.

Our
future success depends on the successful development of our product candidates, some of which may be discovered or developed by our Whole
Proteome Differential Screening target discovery program, or WPDS. WPDS is a new technology, and as such